#Oncology

🏢Release 📈 Stocks

KRAS Inhibitor Market Expands as Roche, Lilly, and Merck Advance Pipelines

October 19, 2026 (14 days ago)

The KRAS inhibitor sector gains momentum as Roche, Eli Lilly, and Merck advance specialized oncology therapies, addressing a growing demand for targeted…

ROG LLY MRK

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals to Present Phase 1 Data for ATNM-400 at EANM 2026

October 19, 2026 (15 days ago)

Actinium Pharmaceuticals will showcase Phase 1 clinical results for ATNM-400 at EANM 2026, targeting advancements in prostate and lung cancer treatments beyond…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

IDEAYA Biosciences Shares Rally on Positive Darovasertib Clinical Data

October 19, 2026 (15 days ago)

IDEAYA Biosciences shares gain momentum as new clinical trial data confirms the efficacy of its darovasertib combination therapy in treating metastatic uveal…

IDYA Servier

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Eli Lilly Previews Oncology Pipeline Data for ESMO Congress Presentation

October 19, 2026 (15 days ago)

Eli Lilly prepares to present key clinical trial updates for its investigational oncology candidates, including sofetabart mipitecan and olomorasib, at the upcoming…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

ESR1 Mutation Research Targets Drug Resistance in Advanced Breast Cancer

October 16, 2026 (17 days ago)

Medical researchers identify ESR1 gene mutations as a primary driver of endocrine therapy resistance in advanced breast cancer, paving the way for…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Shares Rise on Positive ATNM-400 Clinical Data

October 16, 2026 (18 days ago)

Actinium Pharmaceuticals shares gain momentum as new clinical data from EANM 2026 confirms ATNM-400's broad antitumor activity across diverse cancer models, including…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

SenderraRx Secures ACHC Specialty Pharmacy Reaccreditation with Oncology Focus

October 15, 2026 (18 days ago)

SenderraRx maintains its specialty pharmacy standing through a renewed ACHC accreditation, highlighting its continued commitment to oncology-focused patient care and operational quality…

SenderraRx

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

Checkpoint Inhibitor Refractory Cancer Market Projected to Grow Through 2035

October 15, 2026 (18 days ago)

Credence Research forecasts steady growth in the checkpoint inhibitor refractory cancer sector through 2035, fueled by an urgent clinical demand for alternative…

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Phanes Therapeutics Advances Peluntamig for Neuroendocrine Prostate Cancer

October 15, 2026 (18 days ago)

Phanes Therapeutics accelerates the clinical development of Peluntamig (PT217), targeting the growing demand for specialized therapies in the treatment-resistant neuroendocrine prostate cancer…

PHANES

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Bold Therapeutics Hits 60-Patient Enrollment Milestone in Phase 2 Cancer Trial

October 15, 2026 (19 days ago)

Bold Therapeutics reaches the 60-patient enrollment midpoint in its Phase 2 trial for BOLD-100, advancing its clinical development pipeline for novel metallotherapeutics.

Bold Therapeutics

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Actinium Pharmaceuticals Advances ATNM-400 Prostate Cancer Trial

October 15, 2026 (19 days ago)

Actinium Pharmaceuticals moves forward with its Phase 1 trial for ATNM-400, a novel non-PSMA targeted alpha therapy designed to treat metastatic castration-resistant…

ATNM

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eisai Unveils New LENVIMA Oncology Data at ESMO Congress 2026

October 15, 2026 (19 days ago)

Eisai Co. shares new Phase 3 clinical data for its LENVIMA-based oncology pipeline, focusing on advanced renal cell carcinoma treatment efficacy and…

4523.T

🌍 ASIA Read More →